NKMAX Co., Ltd.

NKGen Biotech Completes $16.9M Acquisition of NKMax, Gains Control of NK Cell Manufacturing

- NKGen Biotech acquired a 65% equity stake in Korean biotech company NKMax for $16.9 million, gaining full control of global manufacturing infrastructure and intellectual property assets. - The acquisition transforms NKGen into a vertically integrated NK cell therapy company with enhanced capabilities to advance its lead Alzheimer's treatment, troculeucel. - Troculeucel has received FDA fast track designation and demonstrates cessation of disease progression or cognitive improvements in over 90% of Alzheimer's patients treated to date. - The transaction was funded by AlpineBrook Capital GP 1 Limited and CEO Dr. Paul Y. Song, with NKMax operations now funded through 2026.